Evolus investors frown as FDA declines to approve Botox rival

(Reuters) – U.S. health regulators on Wednesday declined to approve Evolus Inc’s rival product to Allergan Plc’s Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as much as 35 percent.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *